FDA opens floodgates to generics of Bristol-Myers’ Abilify

Eric Palmer

Just hours after Bristol-Myers Squibb beat Wall Street expectations with earnings that got a goose from antipsychotic , the FDA opened the to of the blockbuster.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS